Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogen...

by Irini Genitsaridi, Irini Flouri, Dimitris Plexousakis, Konstantinos Marias, Kyriaki Boki, Fotini Skopouli, Alexandros Drosos, George Bertsias, Dimitrios Boumpas, Prodromos Sidiropoulos
Published 2020-09-01